Key financial ranges
Market cap · USD equivalent
P/E ratio
Annual revenue · USD equivalent
Revenue growth
Valuation & profitability
Price / sales
Annual net income · USD equivalent
Net profit margin
Cash & debt
Cash · USD equivalent
Total debt · USD equivalent
Net cash · USD equivalent
Debt / revenue
| Company | Market cap | P/E | Revenue | Rev. growth | Net income | Cash | Debt | AI value |
|---|---|---|---|---|---|---|---|---|
| STNEStoneCo Ltd. | $2.48B | 4.1× | R$13.26B | +10.0% | -R$1.51B | R$5.23B | R$8.5B | Fair valued |
| BHCBausch Health Companies Inc. | $2.48B | — | $10.27B | +6.7% | $157M | $1.83B | $20.74B | Fair valued |
| HURNHuron Consulting Group Inc. | $2.48B | 23.3× | $1.66B | +11.9% | $105.04M | $26.46M | $887.43M | Fair valued |
| NCNOnCino, Inc. | $2.46B | 77.2× | $594.78M | +10.0% | $5.18M | $83.29M | $338.63M | Fair valued |
| LIFEEthos Technologies Inc. | $2.46B | — | $387.61M | +52.0% | $71.15M | $112.16M | $1.77M | Overvalued |
| STUBStubHub Holdings, Inc. | $2.45B | — | $1.75B | -1.4% | -$1.91B | $1.69B | $1.4B | Fair valued |
| HRMYHarmony Biosciences Holdings, Inc. | $2.45B | 13.6× | $868.45M | +21.5% | $158.69M | $549.77M | $160.19M | Fair valued |
| HCMHUTCHMED (China) Ltd | $2.43B | 139.0× | $548.51M | -13.0% | $456.91M | $71.33M | $122.86M | Fair valued |
| PAYOPayoneer Global Inc. | $2.43B | 51.8× | $813.41M | +14.5% | $73.19M | $346.32M | $14.43M | Fair valued |
| WLYJohn Wiley & Sons, Inc. | $2.43B | 12.5× | $1.68B | -0.1% | $221.62M | $75.62M | $768.9M | Fair valued |
| MLYSMineralys Therapeutics, Inc. | $2.43B | — | — | — | — | $138.27M | $100K | Fair valued |
| MBINMerchants Bancorp | $2.42B | 10.6× | $681.45M | +1.6% | $218.77M | $314.7M | $4.3B | Fair valued |
| MPTMedical Properties Trust Inc | $2.42B | — | $972.02M | -2.4% | -$277.05M | $425M | $9.66B | Fair valued |
| AMCAmc Entertainment Holdings, Inc. | $2.42B | — | $4.85B | +4.6% | -$632.4M | $778.4M | $7.72B | Overvalued |
| ASSTStrive, Inc. | $2.42B | — | $3.65M | +1,217.5% | -$21.58M | $145.47M | $3.32M | Overvalued |
| ASAIYSendas Distributor S.A. | $2.41B | 13.0× | R$73.82B | +11.0% | R$769M | R$5.63B | R$39B | Fair valued |
| CDLRCadeler A/S | $2.41B | 10.0× | €620.35M | +149.4% | €280.18M | €151.68M | €1.71B | Fair valued |
| PURRHyperliquid Strategies Inc | $2.41B | 18.7× | $9.46M | — | $305.54M | $137.92M | — | Fair valued |
| NGVTIngevity Corp | $2.4B | 46.3× | $1.17B | -2.7% | -$167.1M | $97.4M | $1.24B | Undervalued |
| TRVITrevi Therapeutics, Inc. | $2.4B | — | — | — | — | $54.3M | $605K | Overvalued |